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Abstract
Background: Migration of Latin Americans to the USA, Canada and Europe has modified Chagas disease distribution, but
data on imported cases and on risks of local transmission remain scarce. We assessed the prevalence and risk factors for
Chagas disease, staged the disease and evaluated attitudes towards blood transfusion and organ transplant among Latin
American migrants in Geneva, Switzerland.
Methodology/Principal Findings: This cross-sectional study included all consecutive Latin American migrants seeking
medical care at a primary care facility or attending two Latino churches. After completing a questionnaire, they were
screened for Chagas disease with two serological tests (Biome ´rieux ELISA cruzi; Biokit Bioelisa Chagas). Infected subjects
underwent a complete medical work-up. Predictive factors for infection were assessed by univariate and multivariate
logistic regression analysis.1012 persons (females: 83%; mean age: 37.2 [SD 11.3] years, Bolivians: 48% [n=485]) were
recruited. 96% had no residency permit. Chagas disease was diagnosed with two positive serological tests in 130 patients
(12.8%; 95%CI 10.8%–14.9%), including 127 Bolivians (26.2%; 95%CI 22.3%–30.1%). All patients were in the chronic phase,
including 11.3% with cardiac and 0.8% with digestive complications. Predictive factors for infection were Bolivian origin (OR
33.2; 95%CI 7.5–147.5), reported maternal infection with T. cruzi (OR 6.9; 95%CI 1.9–24.3), and age older than 35 years (OR
6.7; 95%CI 2.4–18.8). While 22 (16.9%) infected subjects had already donated blood, 24 (18.5%) and 34 (26.2%) considered
donating blood and organs outside Latin America, respectively.
Conclusions: Chagas disease is highly prevalent among Bolivian migrants in Switzerland. Chronic cardiac and digestive
complications were substantial. Screening of individuals at risk should be implemented in nonendemic countries and must
include undocumented migrants.
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Introduction
Chagas disease is a zoonosis caused by Trypanosoma cruzi (T.
cruzi), a flagellated protozoa transmitted to humans by the faeces of
blood-sucking triatomine bugs. The parasite can also be acquired
by blood transfusion, organ transplant, ingestion of food
contaminated with triatomines or their feces, or congenital
transmission [1]. In 2009, we celebrate the 100
th anniversary of
the first complete description of the disease by Carlos Chagas, a
Brazilian physician. Chagas disease affects eight to ten million
people worldwide and kills more than any other parasitic disease in
Latin America [2]. Until recently, its geographical distribution was
mostly determined by the area of endemicity of the infected
vectors. Successful vector control in endemic countries, urbaniza-
tion, human migration and unpreparedness of newly affected areas
have contributed to modify the distribution of Chagas disease
[3,4]. Non-endemic countries (i.e. countries free of vectors) in
North America, Europe and Western Pacific Region have seen the
recent emergence of Chagas disease following the migration of
more than 15 million people from endemic areas [4]. Estimates of
www.plosntds.org 1 February 2010 | Volume 4 | Issue 2 | e592the total number of T. cruzi infected people living in non-endemic
countries and reported cases are both on the rise, reaching an
estimated 25’000 to 40’000 in Western European countries in
2008. [4–11]. These estimates are usually based on the number of
registered Latin American migrants in the recipient country
multiplied by the mean prevalence of the disease among blood
donors in the home country. This mode of calculation has several
limitations, as it does not include migrants without legal
registration (undocumented), and does not take into account
regional variations of disease prevalence within endemic countries
[12].
Acute T. cruzi infection - frequently asymptomatic - is followed
by a long period of latency with few or no circulating parasites
(indeterminate form of the chronic phase) [1]. After decades, 20–
30% of infected persons develop chronic cardiac or digestive tract
complications. Chronic chagasic cardiopathy (CCC), which is
responsible for the high morbidity, mortality, and socio-econom-
ical impact of the disease in affected areas, is frequently
underdiagnosed, particularly in non-endemic countries [7]. ECG
is the recommended screening test for cardiac damage [13]. Up to
10% of T. cruzi infected persons may develop gastro-intestinal
motility disorder leading to progressive dilatation of the oesoph-
agus (megaoesophagus) and/or the colon (megacolon). Suspected
digestive tract complications are investigated by barium studies.
Specific clinical features of Chagas disease in non-endemic
countries are not well characterized and may differ from those
found in Latin America for various reasons, including different
duration of exposure to infection. Until now, the few published
studies describing disease patterns in Europe were conducted in
specialized centres, and the findings may not be extrapolated to
the global Latin American migrant community [5,14].
Blood-borne transmission of T.cruzi has been reported in several
non-endemic countries [11,15]. Prevalence of infected blood
donations in Europe and North America varies widely, reaching
0.62% in at-risk donors in Spain [15]. Recently, USA, Spain and
France have implemented measures to reduce transfusional risk
through blood donors screening and deferral strategies [11].
However, most European countries that may harbour blood
donors at risk have yet to implement screening measures. The
attitude and practice of Latin American migrants towards blood
donation in non-endemic countries has yet to be investigated.
In 2008, Switzerland hosted 43’000 legal residents originating
from Central and South America [16]. This figure did not include
Swiss nationals from Latin American origin and the estimated 30–
50’000 undocumented Latin American migrants. Undocumented
migrants experience difficulties in accessing medical care in
Switzerland, as health insurance is mandatory and expensive
[17]. The first report of Chagas disease in Switzerland goes back to
1996. Since then, several imported and congenital cases have been
reported [18,19].
The objectives of this descriptive transversal study were to (1)
determine the prevalence of Chagas disease in a community of Latin
American adult migrants living in Geneva, (2) assess the risk factors
for T. cruzi infection, (3) clinically stage the disease, and (4) evaluate
the transfusional and transplantational risk to local recipients.
Methods
Setting
The study took place in a primary care centre (the Community
Care Mobile Unit) of the Geneva University Hospitals which
provides affordable care to more than 2000 Latin American
migrants yearly, the majority of them living in Geneva with
neither residency permit nor health insurance. Privacy is strictly
ensured for undocumented persons. This unit cooperates closely
with representatives of migrants communities. Information about
the study was widely diffused in cultural centres, churches and
migrant associations. In addition, two recruitment sessions took
place in churches attended by migrants.
Participants and procedures
Between June and December 2008, all consecutive adult Latin
American migrants were invited to participate to the study. Other
inclusion criteria were age more than 16 years and signature of an
informed consent form. Pregnant women were excluded from the
study and were referred to the Maternity ward of the Geneva
University Hospitals where a specific program for Chagas
screening has been ongoing since January 2008 [9]. Written
informed consent was requested from participants. Participants
completed a questionnaire (available in Spanish, Portuguese and
French) that collected socio-demographic and medical data, and
assessed their prior and current attitudes towards blood donation
and organ transplant. A multilingual volunteer was available to
help onsite. Serological tests, clinical investigations and treatment
were free of charge. This study was approved by the ethics
committee of the Geneva University Hospitals in January 2008
(protocol 07-285).
Diagnosis of T. cruzi infection
Peripheral blood was drawn by a qualified nurse and serum was
kept refrigerated at 220uC. Two commercialized ELISA-based
serological tests (ELISA cruzi, Biome ´rieux, Brazil and Bioelisa
Chagas, Biokit, Spain), which detect antibodies against crude and
recombinant T. cruzi antigens respectively, were performed
according to manufacturers’ instructions with Dynatech-MRW
Microplate Washer. Chagas disease was diagnosed when both tests
were positive. The two tests were repeated in case of discrepant
results (e.g. positive-negative; doubtful-negative). External quality
control consisted of testing serum samples from all individuals with
positive or discordant ELISA tests and from 10% of individuals
with negative tests (Laboratory of Chagas disease, Goias
University, Brazil). A combination of four serological tests was
Author Summary
Chagas disease, a parasitic disease caused by Trypanosoma
cruzi, is a leading cause of cardiac and digestive tract
disorders in Mexico, Central and South America. An
increasing number of cases have recently been reported
in North America and Europe due to international human
migration, but data outside Latin America remains scarce.
This study showed that Chagas disease is an emerging
health problem in Switzerland, affecting a substantial
proportion of Latin American migrants (13%). Persons at
increased risk of infection were Bolivian, older than 35
years or had a mother infected with T. cruzi. Early signs of
cardiac or digestive tract disease were found in one out of
six infected patients. The risk of local transmission by
blood transfusion or organ transplant was illustrated by
the frequent willingness expressed by patients to donate
blood or organs in Switzerland. The authors recommend
the screening of persons at risk of infection and the
diffusion of appropriate information to the medical
community to increase awareness of this emerging health
problem. Considering that affected persons frequently lack
health insurance in Switzerland, a facilitated access to
medical care is an important step towards better
recognition and management of Chagas disease.
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Bio-Manguinhos, Brasil; Chagatest HAI, Wiener, Argentina; in-
house immunofluorescent test using Biomerieux conjugate,
Biome ´rieux, Brazil). Results were sent back with an integrated
conclusion (positive, negative or non-conclusive).
Staging and management of the disease
All individuals with confirmed T. cruzi infection were contacted
by phone and underwent a clinical evaluation that included full
medical history, physical examination, and a 12-lead electrocar-
diogram (ECG) with a 30-second DII strip. In case of symptoms or
signs suggestive of cardiac failure, history of syncope, or ECG
changes consistent with CCC, an echocardiogram and a 24-hour
Holter recording were performed. Results of cardiac investigations
were independently reviewed by two cardiologists. The classifica-
tion of CCC was based on the Brazilian Consensus [20]. Patients
with dysphagia to solid or liquid food and/or with severe
constipation (less than 2 stools per week and/or use of laxatives
more than 5 days per week for more than 6 months) underwent
gastro-intestinal tract barium examination. Oesophageal abnor-
malities were staged according to the classification of de Rezende
[21]. The colon was considered abnormal if its diameter exceeded
6cm. In the absence of abnormal findings by ECG, echocardiog-
raphy, 24-hour Holter recording, and barium studies, Chagas
disease was classified in the indeterminate form of the chronic
phase. According to recent recommendations, all eligible cases
were treated with nifurtimox or benznidazole for 60 days [13].
Statistical analysis
In order to investigate the relationship between Chagas disease
and possible predictive factors, we used 262 tables and performed
Chi-square and Fisher’s exact tests for categorical variables and
unpaired Student’s t-tests for continuous variables. Univariate and
multivariate logistic regression analyses were used to assess factors
associated with Chagas disease. All analyses were performed using
SPSS for Windows (version 15.0).
Results
Thousand-and-twelve participants, with a mean age of 37.2
(standard deviation (SD) 11.3) years and a female predominance
(83%), were recruited in the study. Ninety-six percent of
participants were undocumented. Countries of origin were Bolivia
(n=485; 48%), Brazil (n=249; 25%), Colombia (n=61; 6%),
Peru (n=58; 6%), Ecuador (n=47; 5%), Paraguay (n=28; 3%),
Nicaragua (n=24; 2%), Honduras (n=24; 2%) and others (n=36;
4%). The mean duration of stay outside Latin America was 4.9
(SD 4.0) years. Socio-demographic characteristics and medical
history data related to T. cruzi infection of the 1012 participants
are shown in Table 1. Previous bite by triatomine bugs were
reported by 11.2% of the participants, 12.7% had received blood
transfusion in Latin America and 7.7% were born from a T. cruzi
infected mother. Previous positive testing for Chagas disease was
reported by 2.6% of participants.
Prevalence of Chagas disease and predictive factors
On the basis of concordant positive serological tests, Trypanosoma
cruzi infection was diagnosed in 130 participants, resulting in an
overall prevalence of 12.8% (95% confidence interval (CI) 10.8–
14.9); prevalence among Bolivians was 26.2% (95%CI 22.3–30.1;
n=127). External quality control confirmed all positive cases.
Three infected individuals originated from Argentina (n=2) and
Brazil (n=1); all had lived for several years in Bolivia. All (n=12)
discordant serological results in Geneva were controlled at the
reference laboratory and proved to be negative. Socio-demographic
characteristics and clinical data of T. cruzi infected individuals
compared to non-infected ones and analysis of factors associated
with infection are shown in Tables 1 and 2, respectively.
Multivariate analysis showed that major predictive factors for T.
cruzi infection were Bolivian origin (adjusted odds ratio (OR 33.2;
95%CI7.5–147.5),maternalinfectionwithT.cruzi(OR 6.9;95%CI
1.9–24.3), and age older than 35 years (OR 6.7; 95%CI 2.4–18.8).
Clinical description
Clinical evaluation was performed in 124 patients (95.4%),
whereas 6 patients were lost to follow-up due to unexpected
departure from Switzerland. Out of 14 patients (11.3%) with ECG
abnormalities consistent with CCC, 12 (9.7%) were classified as
grade A, one as grade B2 (0.8%) and one could not be fully
investigated (Table 3). Twelve (9.7%) other patients with normal
ECG had symptoms or signs consistent with heart disease. Seven of
them underwentfurtherinvestigations.Four hadechocardiographic
signs of low-grade diastolic dysfunction and one showed coronary
sinus dilatation. Two others presented rhythmic abnormalities on
Holter recording. In the absence of definite criteria defined by the
Brazilian consensus, we did not consider these seven patients as
cases of CCC. Twenty-one (16.9%) patients reported dysphagia
(n=10) and/or severe constipation (n=16). Barium studies were
performed in 16 patients. One patient (0.8%) had grade I
oesophageal involvement (Figure 1). 109 (87..9%) patients were
classified as chronic infection in the indeterminate form.
Blood and organ donation
Two-hundred forty seven participants (24.4%) and twenty-two
patients (16.9%) had already donated blood. Twenty-four (18.5%)
and 34 (26.2%) patients expressed willingness to donate blood and
organs outside Latin America, respectively (Table 4).
Discussion
We found a high (12.8%) prevalence of Chagas disease among
1012 Latin American migrants attending an urban primary care
centre and two Latino churches in Geneva, Switzerland. This
figure is much higher than previously reported in Canada (1%)
and Germany (2%), but lower than the very high (41%) prevalence
found at a referral centre in Spain [5,22,23]. Our finding is mostly
explained by the high proportion (48%) of Bolivian migrants in the
study cohort, of whom 26.2% were diagnosed with Chagas
disease. This figure is consistent with recent epidemiological
studies conducted in affected provinces of Bolivia (Santa Cruz,
Cochabamba), where most of the Bolivian migrants living in
Geneva originate from [24,25]. Bolivian participants were not
over-represented in our study as they constitute 42% of Latin
American migrants consulting in our primary care facility.
Bolivian origin was the main predictive factor for T. cruzi infection,
in concordance with other reports from non-endemic countries
[5,9]. Only three of the 130 patients originated from other
countries (Argentina and Brazil). This is unclear whether these
three patients were infected in their country of origin or in Bolivia,
where they lived for several years. The absence of cases diagnosed
in migrants from other endemic countries is likely to be explained
by the insufficient number of persons tested, the possible effect of
cluster sampling (as shown in Bolivians) and the lower average
national prevalence of T. cruzi infection in other Latin American
countries [4]. Nevertheless, cases originating from most Central
and South American countries have been reported in non-
endemic countries [5,14]. Therefore, consideration for T. cruzi
infection should not be restricted to Bolivians.
Chagas Disease in Switzerland
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likely due to a longer and more intense exposition to vectorial
transmission in their home country. Vector control campaigns
have resulted in a sharp reduction of transmission in endemic
countries during the last decades, therefore conferring relative
protection to younger generations [3]. History of maternal
infection (defined by positive serology in the home country) was
also a strong and independent predictive factor for infection. Being
borne from an infected mother cumulates the risk of vertical
transmission and shared exposure to vectorial transmission.
The risk of unrecognized vertical transmission in non-endemic
countries isincreased by the low proportion of patients aware of being
infected, the lack of clinical signs in most infected newborns and the
absence of systematicprenatal screening program [1,9,10]. Screening
should be offered to women of childbearing age, pregnant women
and their offspring (in case of proven maternal infection) [9].
Only 4% of patients had valid residency permit and health
insurance. It is estimated that several millions of migrants at risk
for Chagas disease reside undocumented in Europe and in North
America [4,26]. In many countries, such as Switzerland,
undocumented migrants face difficulties to access preventive and
curative care. This socio-economic dimension must be taken into
consideration by policy makers at the planning stage of screening
programs for Chagas disease in non-endemic countries.
ECG abnormalities consistent with CCC were found in 11.3%
of cases, a proportion comparable to previous reports [5,27]. Most
patients who could be classified were in grade A CCC according to
the Brazilian consensus classification. One patient presented with
advanced stage cardiopathy (grade B2) requiring specific therapy.
Interestingly, five symptomatic patients with normal ECG had
low-grade diastolic dysfunction or coronary sinus dilatation by
echocardiography and two others presented rhythmic abnormal-
ities on Holter recording. In the absence of identified alternative
aetiology, the diagnosis of early stage CCC is possible. However,
the Brazilian criteria do not allow these patients to be classified as
such. More studies are needed to define the diagnostic and
prognostic value of echocardiography and Holter in symptomatic
cases with normal ECG. The low rate of advanced CCC in our
study can be explained by the overall young patients’ age and,
possibly, by the healthy migrant effect. The latter implies that
persons who initiate a long distance migration tend to be healthier
than persons who do not migrate [28]. Nevertheless, cases of
Table 1. Description of Latin American migrants (n=1012) with and without Chagas disease (CD) in Geneva, Switzerland.
Total population N=1012,
Mean (SD) or n (%)
Subjects with CD, N=130, Mean
(SD) or n (% within CD)
Subjects without CD, N=882,
Mean (SD) or n (% without CD) p*
Age (mean) 37.4 (SD 11.3) 41.0 (SD 9.4) 36.9 (SD 11.5) ,0.0001
Age in 2 groups ,0.0001
#35 years 494 (48.8%) 37 (28.5%) 457 (51.8%)
.35 years 518 (51.2%) 93 (71.5%) 425 (48.2%)
Sex (female) 835 (82.5%) 108 (83.1%) 727 (82.4%) 0.85
Origin ,0.0001
Bolivia 486 (47.5%) 127 (97.7%) 359 (40.7%)
other 528 (52.5%) 3 (2.3%) 523 (59.3%)
Years outside Latin America 4.9 (SD 4.0) 4.6 (SD 2.1) 4.9 (SD 4.2) 0.41
Mother with T. cruzi infection ,0.0001
Yes 78 (7.7%) 26 (20.0%) 52 (5.9%)
No 604 (59.7%) 47 (36.2%) 557 (63.2%)
Don’t know 330 (32.6%) 57 (43.8%) 273 (31.0%)
Previous testing ,0.0001
Yes 80 (7.9%) 27 (20.7%) 53 (6.1%)
No 857 (84.7%) 95 (73.1%) 762 (86.4%)
Don’t know 75 (7.4%) 8 (6.2%) 67 (7.6%)
Previous triatomine bite ,0.0001
Yes 113 (11.2%) 35 (26.9%) 78 (8.8%)
Now 336 (33.2%) 20 (15.4%) 316 (35.8%)
Don’t know 563 (55.6%) 75 (57.7%) 488 (55.3%)
Previous transfusion 0.001
Yes 129 (12.7%) 30 (23.1%) 99 (11.2%)
No 879 (86.9%) 100 (76.9%) 779 (88.3%)
Don’t know 4 (0.4%) 0 4 (0.5%)
Previous treatment 0.002
Yes 10 (1.0%) 5 (3.8%) 5 (0.6%)
No 1001 (98.9%) 125 (96.2%) 876 99.3%)
Don’t know 1 (0.1%) 0 1 (0.1%)
*p concerns difference between subjects with and without Chagas disease.
doi:10.1371/journal.pntd.0000592.t001
Chagas Disease in Switzerland
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study period [18,19]. The disease burden and treatment cost of
CCC is recognized as an emerging challenge in some non-
endemic countries like the USA and Spain [8,14]. Only one
patient had radiological evidence of low-grade digestive tract
alteration consistent with Chagas disease. This low prevalence of
digestive tract complications is comparable to findings reported in
Spain [5]. As strict clinical criteria were used before undergoing
barium studies, we can not exclude to have missed one or more
paucisymptomatic case(s).
T. cruzi transmission by blood transfusion has been sporadically
reported in North America and in Europe [1,11,15]. Persistent
parasitemia in infected blood donors can lead to infected donations
over a long period of time [29]. In our cohort, 24.4% participants
and 16.9% of T. cruzi infected patients had a prior history of blood
donation. Despite a relatively short time (mean: 4.9 years) spent
outside Latin America, 6.9% of participants had already donated
blood in North America or in Europe. Moreover, a significant
proportion of participants and of T. cruzi infected patients expressed
the intention to donate blood outside Latin America in the future.
Table 3. Description and staging of patients with Chagas disease and ECG abnormalities in Geneva, Switzerland.
Patient (sex age) Symptoms Signs ECG Echocardiogram Holter Staging
F 28 chest pain none inversed T wave avF normal PVB (576/24h), bradycardia 459 A
F 35 - none partial RBBB normal normal A
F 40 palpitation none inversed T wave v1-v3 normal normal A
F 43 - none AVB grade I normal sustained AT A
F 45 - none RBBB normal PVB (480/24h), PSVB A
F 45 dyspnea, syncope none RBBB normal PSVB, sustained AT A
F 46 - none bradycardia normal PVB (264/24h), PSVB, bradycardia 399 A
F 46 - none PSVB, bigeminisme - - unknown
F 50 dyspnea, chest pain,
palpitation
none LBBB LVEF 35%, global
hypokinesia
PVB (3960/24h), non-sustained VT B2
F 51 syncope none RBBB, bradycardia normal bradycardia 349 A
F 54 chest pain, palpitation none PVB diastolic dsyfunction
grade 2
PVB (9504/24h) A
F 56 - none PVB, LAFB normal PVB (28464/24h), bi-trigeminisme A
F 59 - none inversed T wave v2-v3, q wave
in D1, avL
diastolic dysfunction
grade 1, dilated LA
PVB (432/24h), PSVB, bradycardia 449 A
M 44 chest pain none LAFB, inversed T wave avF normal normal A
RBBB, right bundle branch block; LBBB, left bundle branch block; LAFB, left anterior fascicular block; AVB, atrio-ventricular block; PSVB, premature supra-ventricular beat;
PVB, premature ventricular beat; LA, left atria; AT, atrial tachycardia; LVEF, left ventricular ejection fraction.
doi:10.1371/journal.pntd.0000592.t003
Table 2. Predictive factors, unadjusted and adjusted odds ratios (OR) for Chagas disease (CD) among T. cruzi infected Latin
American migrants in Geneva, Switzerland (n=130).
Prevalence of CD,
n( % )
Unadjusted OR for CD
(95%CI)
Adjusted OR for CDu
(95%CI)




.35 93/518 (18.0%) 2.7 (1.8;4.0) 3.6 (2.3;5.6) 6.1 (2.2;16.7)
Gender
Women 108/835 (12.9%) 1.04 (0.6;1.7) 0.85 (0.5;1.5) 1.04 (0.3;3.4)
Men 22/177 (12.4%)
Origin
Bolivia 127/486 (26.1%) 61.7 (19.5;195.3) 71.2 (22.4;226.4) 31.7 (7.2;139.5)
Other 3/528 (0.6%)
Mother with T. cruzi infection 26/78 (33.3%) 5.9 (3.4;10.3) 6.5 (1.9;22.8)
Mother without T. cruzi infection 47/604 (7.8%)
Previous triatomine bite 35/113 (31.0%) 7.1 (3.9;12.0) 1.8 (0.7;4.6)
No previous triatomine bite 20/336 (6.0%)
uAdjustment for age, sex and origin (patients included in this model: n=1012).
*Adjustment for all variables in table 2 (patients included in this model: n=378).
doi:10.1371/journal.pntd.0000592.t002
Chagas Disease in Switzerland
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proportion of patients unaware of being infected highlights the risk
of blood-borne transmission and support the implementation of
preventive measures in non-endemic countries.
Organ transplant is a rare mode of transmission that has been
reported both in endemic and non-endemic countries [30].
Chagas disease can present as a fulminant systemic disease in
immunosuppressed patients [1]. In our cohort, none of the
participants had donated organs and none of the T. cruzi infected
patients had a previous history of organ transplant. However, a
high proportion of participants and cases considered organ
donation while alive or after passing away. Health professionals
involved in organ transplantation should be informed or reminded
that organ donors or recipients at risk of being infected require
screening for Chagas disease.
The high proportions of migrants with no legal registration and
of Bolivian origin, as well as the recruitment limited to one city,
represent the main limitations of this study as they partially restrict
the extrapolation of our findings to other settings. We believe that
these limitations are counter-balanced by the large population
screened and by the choice of a primary care setting as a
recruitment site. Therefore, our study may offer a valuable insight
into the current trends of this emerging health problem in Europe.
According to our and others’ findings, we recommend screening
for Chagas disease in priority all Latin American persons at
increased chance of (1) infection (e.g. Bolivian origin, diagnosis of
Chagas disease in the mother or in other close family members,
prior history of blood transfusion in endemic countries, presence of
suggestive cardiac or digestive complaints), (2) severe illness (e.g.
immunosuppressed individuals), (3) transmitting T. cruzi to others
(e.g. pregnant women and women of child bearing age, blood or
organ donors), and (4) cure with existing treatments (newborns and
children). Cost-effectiveness studies may help to design more
rational recommendations. Considering the millions of persons at
risk who have recently migrated outside Latin America, medical
students and physicians in non-endemic countries must be made
aware of the emergence of this neglected tropical disease.
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Figure 1. Gastro-oesophageal barium examination in left
posterior oblique view in upright position in a T. cruzi infected
individual showing delayed bolus elimination without oesoph-
ageal dilatation (de Rezende stage I) one minute after
ingestion.
doi:10.1371/journal.pntd.0000592.g001






Migrants with Chagas disease
(n=130) N (%)
History of blood donation 247* (24.4) 109 (22.4) 22 (16.9)
in Latin America 208 (84.2) 96 (88.1) 22 (100)
in Europe 17 (6.9) 1 (0.9) 0
not stated 27 (10.9) 13 (11.9) 0
Intention to give blood outside Latin America 206 (20.4) 70 (14.4) 24 (18.5)
History of organ donation 00 0
Intention to give organ 360 (35.6) 149 (30.7) 34 (26.2)
*Five individuals have donated blood in more than one geographical region.
doi:10.1371/journal.pntd.0000592.t004
Chagas Disease in Switzerland
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Found at: doi:10.1371/journal.pntd.0000592.s002 (0.09 MB
DOC)
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